Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire Files Treatment Protocol For Gaucher Disease
Shire, at the request of the FDA, has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development, for the treatment of Gaucher Disease. Velaglucerase
Shire, at the request of the FDA, has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development, for the treatment of Gaucher Disease. Velaglucerase
Natus Medical has acquired Massachusetts based Hawaii Medical. Hawaii Medical manufactures and markets single-use disposable products sold into the NICU and nursery in hospitals. Natus acquired Hawaii Medical
Spectrum Pharmaceuticals has received a complete response letter from the US Food and Drug Administration (FDA). The response was regarding its supplemental Biologics License Application (sBLA) for ZEVALIN
The US Food and Drug Administration (FDA) has warned consumers not to buy or use Hardcore Energize Bullet or New Whey liquid products sold in test tube-like vials,
Chondrometrics has announced that ArthroVision, a wholly-owned subsidiary of Horizon Sciences & Technologies, has accepted the decision of the District Court of Munich, Germany. As per the court
Tests performed in the laboratories of AMP members have had a significant impact on the understanding and treatment of chronic conditions such as HIV, cancer, heart disease, diabetes,
European Commission has granted marketing authorisation for Novo Nordisk’ Victoza, for the treatment of type 2 diabetes in adults. The authorisation covers all 27 EU member states. Victoza
Kissei Pharmaceutical announced that GlaxoSmithKline has discontinued the development of the novel agent for diabetes, remogliflozin (KGT-1681). It was as a result of evaluating circumstances including the development
BioCis has announced positive results from phase IIa clinical trial of ProtoCure emulsion cream, a new topical drug for dermatology. The double-blind, placebo-controlled study was conducted in Finland.
Cougar has announced that the initial offering period of Johnson & Johnson’s (J&J) tender offer, for all the outstanding shares of Cougar common stock, expired on July 2,